1 – 20 of 24
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms
(
- Contribution to journal › Article
-
Mark
Plasma Biomarker Strategy for Selecting Patients with Alzheimer Disease for Antiamyloid Immunotherapies
(
- Contribution to journal › Article
- 2023
-
Mark
Age-related and amyloid-beta-independent tau deposition and its downstream effects
(
- Contribution to journal › Article
-
Mark
Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes
(
- Contribution to journal › Article
-
Mark
Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
(
- Contribution to journal › Article
- 2022
-
Mark
Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
(
- Contribution to journal › Article
-
Mark
Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
(
- Contribution to journal › Article
-
Mark
Age-related tau-PET uptake and its downstream effects extend beyond the medial temporal lobe in cognitively normal older adults
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Earlier Alzheimer's disease onset is associated with a shift of tau pathology towards brain hubs which facilitates tau spreading
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease
(
- Contribution to journal › Article
- 2021
-
Mark
A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis
(
- Contribution to journal › Article
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
-
Mark
Associations of Plasma Phospho-Tau217 Levels with Tau Positron Emission Tomography in Early Alzheimer Disease
(
- Contribution to journal › Article
-
Mark
Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers
(
- Contribution to journal › Article
-
Mark
Early stages of tau pathology and its associations with functional connectivity, atrophy and memory
(
- Contribution to journal › Article
- 2020
-
Mark
Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
The implications of different approaches to define AT(N) in Alzheimer disease
(
- Contribution to journal › Article